Multi-institutional analysis of T3 subtypes and adjuvant radiotherapy effects in resected T3N0 non-small cell lung cancer patients.
- Author:
Yunseon CHOI
1
;
Ik Jae LEE
;
Chang Young LEE
;
Jae Ho CHO
;
Won Hoon CHOI
;
Hong In YOON
;
Yun Han LEE
;
Chang Geol LEE
;
Ki Chang KEUM
;
Kyung Young CHUNG
;
Seok Jin HAAM
;
Hyo Chae PAIK
;
Kang Kyoo LEE
;
Sun Rock MOON
;
Jong Young LEE
;
Kyung Ran PARK
;
Young Suk KIM
Author Information
- Publication Type:Original Article
- Keywords: Non-small cell lung cancer; Adjuvant radiotherapy; Prognostic factor
- MeSH: Carcinoma, Non-Small-Cell Lung*; Diaphragm; Disease-Free Survival; Humans; Joints; Pleura; Prognosis; Radiotherapy, Adjuvant*; Thoracic Wall
- From:Radiation Oncology Journal 2015;33(2):75-82
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: We evaluated the prognostic significance of T3 subtypes and the role of adjuvant radiotherapy in patients with resected the American Joint Committee on Cancer stage IIB T3N0M0 non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: T3N0 NSCLC patients who underwent resection from January 1990 to October 2009 (n = 102) were enrolled and categorized into 6 subgroups according to the extent of invasion: parietal pleura chest wall invasion, mediastinal pleural invasion, diaphragm invasion, separated tumor nodules in the same lobe, endobronchial tumor <2 cm distal to the carina, and tumor-associated collapse. RESULTS: The median overall survival (OS) and disease-free survival (DFS) were 55.3 months and 51.2 months, respectively. In postoperative T3N0M0 patients, the tumor size was a significant prognostic factor for survival (OS, p = 0.035 and DFS, p = 0.035, respectively). Patients with endobronchial tumors within 2 cm of the carina also showed better OS and DFS than those in the other T3 subtypes (p = 0.018 and p = 0.016, respectively). However, adjuvant radiotherapy did not cause any improvement in survival (OS, p = 0.518 and DFS, p = 0.463, respectively). Only patients with mediastinal pleural invasion (n = 25) demonstrated improved OS and DFS after adjuvant radiotherapy (n = 18) (p = 0.012 and p = 0.040, respectively). CONCLUSION: The T3N0 NSCLC subtype that showed the most favorable prognosis is the one with endobronchial tumors within 2 cm of the carina. Adjuvant radiotherapy is not effective in improving survival outcome in resected T3N0 NSCLC.
